Academisch Ziekenhuis Maastricht

Maastricht UMC+ Develops Promising Drug for Hereditary Fructose Intolerance Treatment

3 months ago

• Researchers at Maastricht UMC+ have successfully tested a novel drug that blocks toxin accumulation in patients with hereditary fructose intolerance, potentially eliminating the need for strict dietary restrictions. • Clinical trials with three patients demonstrated successful fructose excretion through urine without triggering symptoms, marking a significant breakthrough for the rare metabolic disorder. • The development offers hope to approximately 200 patients in the Netherlands with hereditary fructose intolerance, who currently must maintain strict fructose-free diets to avoid severe health complications.

Radiopharmaceutical Antibody-Drug Conjugates (rADCs) Emerge as Promising Cancer Therapies

9 months ago

• rADCs are designed to deliver radiation directly to cancer cells, minimizing side effects compared to traditional radiation therapy. • Several companies are developing rADCs with various radioisotopes and antibodies, targeting cancers like prostate, breast, and lung cancer. • Clinical trials are underway to assess the efficacy and safety of rADCs, showing promising results in reducing tumor markers like PSA. • Challenges remain in supply chain logistics, dosimetry, and optimizing drug delivery to target tissues for effective cancer treatment.